| Autor: |
D. Sureshkumar, G Pavithra, N Hari, K Balakrishnan |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 134, Iss , Pp S22- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2023.07.024 |
| Popis: |
Intro: β-lactam/β-lactamase inhibitor (BLBLI) and carbapenem are often used antibiotics in developing countries for sepsis due to the high occurrence of gramnegative infections with ESBL producing organisms. Current western guidelines advice that carbapenem is the drug of choice for gram-negative infections. However, carbapenem resistance is raising in the developing world and BLBLI is equally effective to carbapenem and cost effective. The aim of this study is to compare BLBLI with carbapenem. Methods: This prospective observational study was conducted in tertiary care hospital in India for 4months. Data regarding demographics, antibiotic therapy, side effects and sensitivity of both groups were collected by Pharm-D interns from the medical records and analysed using SPSS version 26.0. Findings: During the study period 321 subjects were receiving BLBLI and CARBAPENEM. The comparative data is shown on the table. Conclusion: The aim of this study is to compare BLBLI with carbapenem. Efficacy of BLBLI (94.77%) is equivalent to carbapenem (94.03%), as far as efficacy is concerned safe. Safety of BLBLI (58.53%) is better than carbapenem (42.03%). Sensitivity of BLBLI (79.76%) is less compared to carbapenem (91.17%). It is a single-centric study; However, the finding should be confirmed in large randomized control trial to evaluate more efficiently. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
